Abstract: Methods, kits, and compositions are provided herein that can be used to treat ovarian cancer using an anti-CD47 antibody. The anti-CD47 antibody can be used alone or in combination with one or more additional agent such as chemotherapy.
Type:
Grant
Filed:
October 18, 2018
Date of Patent:
October 31, 2023
Assignee:
Forty Seven, Inc.
Inventors:
Chris Hidemi Mizufune Takimoto, Mark Ping Chao, Jens-Peter Volkmer
Abstract: A method of treating inflammatory bowel disorders, such as ulcerative colitis, comprises administering an IL-23 inhibitor, such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-? inhibitor, such as an anti-TNF-? antibody (e.g., golimumab).
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
October 10, 2023
Assignee:
JANSSEN BIOTECH, INC.
Inventors:
Matthew Germinaro, Christopher O'Brien, Jacqueline Perrigoue
Abstract: Disclosed herein are SERPIN peptides, and analogues and derivatives thereof, and uses of the same for treating various conditions associated with LRP1 mediation.
Abstract: Provided herein are methods for treating cancer in a patient who has been determined to have positive expression of CD200 receptor (CD200R1) and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) by administering to the patient a CD200 inhibitor. Also provided are methods for monitoring responsiveness of a patient having cancer to treatment with a CD200 inhibitor, the method comprising: determining expression levels of CD200R1 and one or more biomarkers (i.e., ICOS, TIGIT, TNFRSF9, HAVCR2, PDCD1, FCGR2A, FCGR1A, CD163, and/or CD14) in a biological sample from the patient, wherein increased expression levels of CD200R1 and the one or more biomarkers, as compared to expression levels in a biological sample of the same type obtained from the subject prior to treatment with the CD200 inhibitor, indicates that the subject is responsive to treatment with the CD200 inhibitor.
Abstract: Provided herein are separation moieties that are suitable for use in conjunction with a variety of therapeutic payloads. The separation moieties serve to generate conditionally active macromolecules whereby the macromolecules have reduced or minimal biological activity until the separation moieties are modified under specific conditions.
Type:
Grant
Filed:
February 22, 2022
Date of Patent:
August 29, 2023
Assignee:
Werewolf Therapeutics, Inc.
Inventors:
William Winston, Luke Evnin, Vinay Bhaskar, Giselle Knudsen, Daniel J. Hicklin, Cynthia Seidel-Dugan, Jose Andres Salmeron Garcia, Heather R. Brodkin
Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
Type:
Grant
Filed:
April 10, 2020
Date of Patent:
August 29, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.
Type:
Grant
Filed:
June 16, 2020
Date of Patent:
August 15, 2023
Assignee:
Genentech, Inc.
Inventors:
Philip E. Hass, Meredith Hazen, Yi-Chun Hsiao, Rajita Khosla, Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Hongkang Xi, Wenwu Zhai, Jack Bevers, III, Nancy Chiang
Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).
Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
Type:
Grant
Filed:
May 26, 2022
Date of Patent:
June 20, 2023
Assignee:
Altor Bioscience, LLC.
Inventors:
Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
Abstract: The disclosure relates to compounds specific for IL23A and TNF-alpha, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
Type:
Grant
Filed:
August 26, 2020
Date of Patent:
June 20, 2023
Assignees:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH, MACROGENICS, INC.
Inventors:
Rachel Rebecca Barrett, Leslie S. Johnson, Sanjaya Singh, Kathleen Last-Barney, Daw-Tsun Shih, Patricia Giblin, Scott Brodeur, Nelamangala Nagaraja
Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.
Type:
Grant
Filed:
April 8, 2022
Date of Patent:
June 13, 2023
Assignee:
Altor Bioscience, LLC.
Inventors:
Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-Ping Han
Abstract: Provided herein are monoclonal antibodies that specifically bind IL-13RA2 with cross-reactivity in humans and canines. Also provided are methods of use of the antibodies in the treatment and monitoring of cancers.
Abstract: The present application provides methods of administering an IL-22 dimer to an individual, such as a human individual, comprising intravenously administering to the individual an effective amount of an IL-22 dimer, wherein the amount of the IL-22 dimer is about 2 ?g/kg to about 200 ?g/kg (such as about 10 ?g/kg to about 45 ?g/kg), as well as methods of treating diseases by following such administration methods. Also provided are kits, unit dosages, and articles of manufacture for use in any one of the methods described herein.
Abstract: Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.
Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.
Abstract: The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.
Type:
Grant
Filed:
December 7, 2018
Date of Patent:
May 9, 2023
Assignees:
The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of California
Inventors:
Rajni Agarwal, Janel Long Boyle, Morton J. Cowan, Christopher Dvorak, Hye Sook Kwon, Anne Le, Aaron Logan, Wendy Pang, Robertson Parkman, Maria-Grazia Roncarolo, Kenneth Weinberg, Judith A. Shizuru, Susan Sweeney Prohaska, Agnieszka Czechowicz, Irving L. Weissman
Abstract: The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human IL2 receptor gamma (IL2R?). Methods for treating or preventing diseases mediated by IL2R? (e.g., graft vs host disease) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.
Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.
Type:
Grant
Filed:
May 20, 2022
Date of Patent:
April 11, 2023
Assignee:
SORRISO PHARMACEUTICALS, INC.
Inventors:
Scott Crowe, Marion Cubitt, Tim Carlton, Luana Maggiore, Lurdes Duarte, Kevin Roberts, Mike West
Abstract: Administration regimens for therapeutic proteins (e.g., T cell-activating bispecific antibodies) that mitigate cytokine release syndrome and infusion-related reaction are disclosed. The methods employ initial fractional dosing with optional administration of additional agents such as steroids or cytokine antagonists that are discontinued with maximal weekly dosing over the course of the dosing regimen.
Type:
Grant
Filed:
August 30, 2019
Date of Patent:
February 28, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Carrie Brownstein, Israel Lowy, Lieve Lucille Adriaens